Evotec 566480, wohin geht die Reise??? (Seite 6518)

[akfan]

Service Overview

IR Pharma aims to provide a flexible approach to commercial needs and can implement drug discovery plans ranging from large, multi-stage, comprehensive programmes through to more compact projects designed to address single aspects within the discovery pathway.

Many factors contribute to the outstanding capability and service offered by IR Pharma that are echoed in surveys of customer satisfaction concerning outplacement decisions. These include;

* A multi-faceted and multi-skilled team, able to work competently across the full range of techniques and disciplines required in the provision of a comprehensive pharmacology capability
* Access to current scientific thinking within a world-leading research and discovery team
* A service attuned to industry needs through an extensive and successful background in respiratory drug discovery within the pharmaceutical industry
* Continuous refinement of existing methodology, and development of new assays and techniques that reflect current knowledge to provide high quality evaluation studies undertaken according to best practise
* An extensive range of assays, models, and evaluation methodology geared to the discovery pathway that spans early stage lead compound validation through to pre-clinical trial evaluation, utilising clinical tissue samples

Importantly all study plans are strategically conceived with a view to follow-on steps, should this be warranted In essence this ensures all projects receive an element of high level consultancy as a matter of routine.

It is, therefore, possible to take a modular view of lead molecule evaluation with movement to each successive stage of the discovery pathway as, and when, movement to the next step becomes justified.

Alternatively, we can design and implement a systems based comprehensive and fully integrated pre-clinical assessment campaign, to advance lead candidates to a stage where they have been assessed using clinical-sample models prior to entering clinical trial.

It is this unrivalled capability that ensures every study is designed to deliver optimal value.

[akfan]

IR Pharma Ltd - Company Overview

IR Pharma provides the pharmaceutical industry with Respiratory Pharmacology pre-clinical drug discovery through short, focused projects and larger, wide ranging system-based discovery programmes. Timely delivery of study objectives that add value to client lead compounds and technology are high priority for the company.

Based on the world leading academic expertise of the Respiratory Pharmacology group at the National Heart and Lung Institute, Imperial College, led by Professor Maria Belvisi and Dr Mark Birrell, the team, additionally can boast an extensive industry background. They have been providing an outstanding combination of scientific insights and practical solutions to address the pre-clinical needs of industry clients for several years.

With the formation of IR Pharma Ltd, this expertise was placed on a commercial footing intended to provide clients with easy access to discovery expertise through a business-attuned process that is fully conversant with industry needs and timelines. The aim of the IR Pharmacology team is to provide clients with a customer friendly system, addressing their needs through provision of:

* A responsive business interface for addressing enquiries
* Rapid early feedback on project feasibility
* Quick and efficient movement to contract

The quality of the service provided by IR Pharma is endorsed by its prestigious list of past clients that have chosen the IRP team to evaluate their lead compounds and delivery technology. Projects include evaluation of drugs for treatment of the major respiratory conditions and drugs that must be delivered via the respiratory route. In addition to general mechanistic models, specific disease model are available in;

* Asthma
* Chronic Obstructive Pulmonary Disease (COPD)
* Disease Cough

Whatever the problem or need, we believe IR Pharma can provide an unrivalled combination of assays, models and current scientific thinking to provide solutions that represents outstanding value.

[brotherchris]

Evotec und IR Pharma vereinbaren Partnerschaft im Bereich Atemwegserkrankungen (deutsch)
Autor: dpa-AFX | 16.02.2012, 07:26 | 10 Aufrufe | 0 |
Evotec und IR Pharma vereinbaren Partnerschaft im Bereich Atemwegserkrankungen


DGAP-News: Evotec AG / Schlagwort(e): Kooperation

Evotec und IR Pharma vereinbaren Partnerschaft im Bereich

Atemwegserkrankungen


16.02.2012 / 07:26


---------------------------------------------------------------------


Hamburg, Deutschland - 16. Februar 2012: Evotec AG (Frankfurt Stock

Exchange: EVT, TecDAX) und IR Pharma gaben heute die Vereinbarung einer

exklusiven, strategischen Allianz bekannt, um integrierte

Wirkstoffforschungslösungen im Bereich der Atemwegserkrankungen für Pharma-

und Biotechnologieunternehmen anzubieten.


Diese Allianz verbindet Evotecs umfassende Wirkstoffforschungsplattform mit

der weltweit führenden Expertise in der In-vitro- und In-vivo-Pharmakologie

von IR Pharma im Bereich Atemwegserkrankung. Zudem ist Evotec mit dieser

exklusiven Kollaboration in der Lage, seinen Partnern fokussierte,

vollintegrierte Forschungsprogramme in dem Bereich der Atemwegs- und

Entzündungskrankheiten anzubieten und zwar vom Target bis hin zum

präklinischen Entwicklungskandidaten.


Dr Mario Polywka, Chief Operating Officer von Evotec, kommentierte: 'Wir

freuen uns auf die Zusammenarbeit mit IR Pharma und sind von dem Potential

dieser Allianz überzeugt. IR Pharma verfügt über herausragende Expertise

im Bereich der Atemwegserkrankung, die auch krankheitsrelevante In-vivo-

Modelle umfasst. Verbunden mit unserer weltweit führenden

Forschungsplattform und kommerziellen Reichweite wird diese Zusammenarbeit

einen wertvollen Beitrag für unsere Partner in diesem komplexen

Krankheitsfeld leisten. Diese Kooperation ist eine signifikante Erweiterung

unserer Strategie, um unseren Partnern noch umfangreichere

Forschungslösungen anbieten zu können.'


Prof Maria Belvisi, Director von IR Pharma Ltd, fügte hinzu: 'Wir sind

erfreut, unsere Fähigkeiten mit Evotec zu vereinen und sind fest davon

überzeugt, dass wir gemeinsam unseren Partnern effiziente und innovative

Forschungslösungen anbieten können. Wir verfügen über eine Bandbreite

validierter Modelle, fokussiert auf Asthma, Husten und chronisch

obstruktiver Lungenkrankheit (COPD), die Evotecs Plattform ideal ergänzen.

Dies ermöglicht uns einen vollintegrierten Forschungsansatz in diesem

herausfordernden Bereich.'


Einzelheiten zu den finanziellen Details wurden nicht bekanntgegeben.



Kontakt Evotec AG:

Dr. Werner Lanthaler, Vorstandsvorsitzender, Tel.: [phone],

[e-mail]



Ende der Corporate News


---------------------------------------------------------------------


16.02.2012 Veröffentlichung einer Corporate News/Finanznachricht,

übermittelt durch die DGAP - ein Unternehmen der EquityStory AG.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber

verantwortlich.


Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,

Corporate News/Finanznachrichten und Pressemitteilungen.

Medienarchiv unter http://www.dgap-medientreff.de und

http://www.dgap.de


---------------------------------------------------------------------



Sprache: Deutsch

Unternehmen: Evotec AG

Manfred Eigen Campus / Essener Bogen 7

22419 Hamburg

Deutschland

Telefon: [phone]

Fax: [phone]

E-Mail: [e-mail]

Internet: www.evotec.com

ISIN: DE0005664809

WKN: 566480

Börsen: Regulierter Markt in Frankfurt (Prime Standard);

Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,

München, Stuttgart



Ende der Mitteilung DGAP News-Service

---------------------------------------------------------------------

156962 16.02.2012

[altonaer]

kannst du mir bitte erklären, woran man erkennt, das gedeckelt wird.

[depulep]

man sieht heute wieder mal wie evo
gedeckelt wird
bloß we steckt dahinter
der trend is mei frend

[Ackergaul]

Viel Stoff zum Lesen (zu RG1577 bzw. EVT302) aber es stecken einige "interessante Sachen" drin...
Roche/Evotec's EVT 302 may be viable alternative in
Alzheimer's, though disease modifying potential
questione
Roche (VTX:ROG)/Evotec's (ETR:EVT) EVT 302 has high selectivity for monoamine oxidase B
(MAO-B) which could present a neuroprotective approach in Alzheimer's disease (AD) and offer
improved tolerability, according to experts. However, some questioned its disease modifying
potential in AD.
Evotec's EVT 302 could slow disease progression by inhibiting the MAO-B enzyme, which
breaks down dopamine in the brain and contributes to the production of free radicals, according
to the company website. Free radicals are known to cause oxidative stress which may
contribute to pathogenesis of AD, the website notes.
In September Roche announced a licensing deal with Evotec for the development and
comercialisation rights to EVT 302 in AD; Roche will be responsible for all R&D costs. Roche
had originally licensed the drug to Evotec in 2006 for development in smoking cessation where
the drug failed to demonstrate a benefit in a Phase II trial. The companies will initiate a Phase
IIb trial in AD as fast as possible in 2012, Evotec CEO Dr Werner Lanthaler told this news
service in September. The Phase IIb trial will be very large to ensure there is enough data to
make a good decision on the Phase III programme, Lanthaler noted.
Evotec is not claiming there is scientific rationale for EVT 302 to work in AD, yet there is the
hypothesis that MAO-B plays a role in oxidative stress, Lanthaler said. Evotec is realistic and is
not expecting EVT 302 will cure AD but it may have an impact on the disease, he added.
Teva's (NASDAQ:TEVA) marketed drug rasagiline (Azilect), a MAO-B inhibitor, is currently
used for the treatment of Parkinson's disease as a monotherapy or as an adjunctive treatment
to levodopa.
Dr Luca Santarelli, discovery and translational area head for CNS at Roche Pharma Research
and Early Development, noted that Azilect demonstrates limited selectivity for MAO-B and also
demonstrates some inhibition of MAO-A. Since MAO-A plays a major role in metabolism of
monoamine neurotransmitters, this may increase the risk of rare but potentially dangerous
pharmacodynamic interaction with drugs that modulate monoaminergic transmission, such as
antidepressants, he said.
EVT 302 is a potent, selective, fully reversible, non-covalent MAO-B inhibitor, Santarelli said,
noting the agent belongs to a new generation of MAO-B inhibitors with a novel chemical
structure. It has very high selectivity for MAO-B, allowing for complete MAO-B inhibition without
affecting the enzymatic activity of MAO-A, even after chronic use, he said. Santarelli added the
high selectivity of EVT 302 is expected to translate into an improved tolerability and safety
profile. The Phase I and Phase II studies conducted at Evotec support this notion, he added.
Lanthaler indicated EVT 302 has a "perfect toxicity profile" and the data supports the
hypothesized mechanism of action even at a small dose.
For EVT 302 to have neuroprotective properties through prevention of the oxidative stress
mechanism, it needs to specifically target the mitochondria on the outer membrane of cells,
said principal investigator Hemachandra Reddy at the Oregon Health & Science University. If it
truly can prevent free radicals then it may have some potential, Reddy said. The idea is that by
reducing mitochondrial stress, it is possible to reduce oxidation and therefore prevent cells from
dying, he explained.
However, according to Dr Sam Gandy, associate director of the Mount Sinai Alzheimer's
Disease Research Center, while MAO-B inhibition has a role in arousal and attention, such an
approach would not be considered a disease modifying treatment. He said he does not see
anything in the mitochondrial hypothesis that would imply an MAO-B inhibitor has disease
modifying potential and added EVT 302 is likely to be limited as a symptomatic therapy in AD.
For EVT 302 to be really neuroprotective, it also needs to cross the blood brain barrier at a
sufficient concentration and it is important that there is good evidence for its proposed activity in
several mouse models, Reddy said.
According to Moussa Youdim, Finkelstein Professor of Neuroscience and Professor of
Pharmacology and Biomedical Engineering at the Technion Israel Institute of Technology in
Haifa, Israel, MAO-B is increased in the astrocytes of patients with AD. He added he believes
MAO-B inhibition can demonstrate neuroprotection and that Azilect has a disease modifying
role in Parkinson's due to its neuroprotective effects.
The FDA, however, decided last month that Azilect would not attain a label for neuroprotection
based on the ADAGIO trial, which sought to demonstrate the agent's disease modifying
potential.
Dr Howard Fillit, president of the Alzheimer's Drug Discovery Foundation (ADDF), said the
foundation is supporting the development of MAO-B inhibitors in AD. According to Fillit, such
agents have broader implications beyond their neurotransmitter effects as they demonstrate
antioxidant and neuroprotective properties.
For example, the ADDF supported work by the Technion Israel Institute of Technology on
ladostigil (TV-3,326), which acts as a reversible acetylcholinesterase and butyrylcholinesterase
inhibitor and an irreversible MAO-B inhibitor. It combines the mechanisms of action of older
drugs like rivastigmine and Azilect into a single molecule
The MAO-B inhibitor projects supported by the ADDF are investigating multifunctional agents
that combine several targets rather than simply targeting MAO-B, Fillit indicated. These drugs
have potential because they could impact the disease with their multifunctional sum, he said,
explaining that the sum effect of these targets is likely to be greater than the parts. Yet he
added that MAO-B inhibition is worth studying by itself.
In September 1999, Roche discontinued development of lazabemide, also a MAO-B inhibitor,
after isolated reports of serious renal complications associated with the drug. The drug was
under review for approval in the treatment of Parkinson's disease and in Phase III AD trials.
Lazabemide had shown promising results in AD according to company information.
by Abigail Moss and Anusha Kambhampatyd

===========================================


Roche Bets up to $830M On Evotec's MAO-B for AD
BioWorld Today Correspondent
LONDON – Evotec AG has out-licensed its lead monoamine oxidase type B (MAO-B) product for Alzheimer's disease in a $830 million deal with Roche AG, taking
$10 million up front, followed by short-term clinical milestones of $170 million and the balance to come in commercial milestones.
In addition, Roche is assuming all development and commercialization costs. The Basel, Switzerland-based pharma will start a large Phase IIb trial in 2012
powered to demonstrate that the orally available product, EVT 302, slows the progression of symptoms of Alzheimer's, and paving the way for a pivotal Phase III
study.
The compound was originally licensed from Roche to Evotec in 2006, and was initially developed as a smoking cessation treatment. In May 2009 it failed to
demonstrate efficacy in a Phase II proof-of-concept trial involving 414 smokers in which EVT 302 was tested alone and in combination with a nicotine replacement
patch.
An earlier MAO-B inhibitor, EVT 301, also licensed from Roche, failed in a Phase I program in the treatment of Alzheimer's disease in 2006.
Werner Lanthaler, CEO of Evotec, said he is "very happy" Roche has decided to take back EVT 302, in what he claimed will be "the largest effort" in Alzheimer's
disease drug development, with the clinical program costing "more than €100 million" (US$140.07 million).
While he was not prepared to give a specific timetable, Lanthaler said the clinical development program will be very fast, with Roche currently preparing for the
Phase IIb.
"There will be full commitment and full speed. It will be much faster than many people think," he said during a conference call held to discuss the deal.
To date, no drug has demonstrated the ability to slow the progress of Alzheimer's disease, with all Phase III trials that have reported to date failing, Lanthaler
noted. Meanwhile, drugs targeting the beta-amyloid pathway are yet to achieve proof of concept.
"The Evotec/Roche MAO-B program represents an alternative and potentially complementary approach [to beta-amyloid targeted drugs]," Lanthaler said.
Lanthaler claimed Hamburg, Germany-based Evotec has overcome the interaction with dietary tyramine seen with previous MAO-B inhibitors, saying EVT 302
has "a perfect safety profile."
He added, "We think it is the perfect molecule to test in Alzheimer's disease; Evotec has produced a robust clinical and preclinical development package."
MAO-B is responsible for the breakdown of certain neurotransmitters in the brain, and its activity is linked to the production of reactive oxygen species, causing
oxidative stress and neuronal damage. The enzyme has been shown to be overexpressed in the postmortem brains of Alzheimer's sufferers, and it is proposed that
blocking its activity will slow progression of the disease.
Evotec's Phase I data include PET studies that show it is possible to completely inhibit production of MAO-B with orally administered EVT 302. There were no
safety or tolerability concerns with dosing of up to eight weeks.
In September 2006 Evotec discontinued development of the earlier compound EVT 301, following indications of potential liver toxicity in a Phase I trial in healthy
volunteers. Roche had earlier put EVT 301 through five Phase I trials, but all of those were of a shorter duration, and did not highlight the liver toxicity.
EVT 301 was related to a predecessor MAO-B inhibitor, which had failed a Phase III trial in Alzheimer's, the results of which were not published. EVT 302 has a
different chemistry from the earlier compounds.
Evotec has kept faith with the potential of MAO-B inhibition in Alzheimer's disease, pushing on with the development at a time when most of the other drugs in
late-stage development for Alzheimer's, such as Eli Lilly and Co.'s solanezumab, Genetech's crenezumab and Roche's gantenerumab, target the beta-amyloid
pathway.
Lanthaler said targeting MAO-B represents both a true alternative and a potential additive approach to beta-amyloid.
Published: September 7, 2011


Grüße

[bruder_halblang]

Zitat von depulep: zäh schleppender handel
wen interessiert israe
is denn hier kana da
der handel is doch der blanke fake
oder nicht vorhanden
ab 2,81 wirds wieder reall

Ihr seid doch nur zu sehr verwöhnt von den letzten Börsenwochen. Der derzeitige Handel ist Normalität. Selbst wenn die Märkte nicht erneut abstürzen sollten, muss hier dennoch die 2,40 wieder einkalkuliert werden. Das kann ganz schnell gehen und wäre nur Normalität. Wichtig ist, dass man derzeit nicht mehr voll investiert ist!

[depulep]

zäh schleppender handel
wen interessiert israe
is denn hier kana da
der handel is doch der blanke fake
oder nicht vorhanden
ab 2,81 wirds wieder reall

[spero]

@evotecci
... oder liegt die wissenschaftliche Leitung für DiaPep277 immer noch in Göttingen bei ex DeveloGen ?

[spero]

Unser größter Hoffnungsträger ist momentan wohl DiaPep277. Was passiert eigentlich, wenn Israel in diesem Frühjahr tatsächlich den Iran angreift ? (Ich fürchte, wir werden medial systematisch darauf vorbereitet.)

Das Öl wird richtig teuer, die Märkte werden heftig einbrechen. Bleibt zu hoffen, dass EVO als Nebenwert nicht so stark betroffen sein wird. Es sei denn ...

... die Hisbollah wird von den Iranern von der Kette gelassen werden und die tragen den Krieg nach Israel hinein. Tavea/Andomeda haben ihren Sitz in Israel, gewissermaßen die Heimat von DiaPep277 ... Gefahr für unseren Hoffnungsträger ?

@Ackergaul
Du treibst dich doch ständig in internationalen Gewässern herum. Ist dir der Gedanke schon mal irgendwo begegnet ?

@evotecci
Da die laufenden klinischen Studien sowieso international angelegt sind, könnte man im Krisenfall die wissenschaftliche Leitung aus der Schussline nehmen und nach Hamburg oder sonst wohin verlegen ?


spero